Company intelligence / Profile preview
Winston Pharmaceuticals
United Stateswinston.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Historically, Winston Pharmaceuticals developed small molecule drugs for pain management, with a main asset (civamide nasal solution for cluster headache) reaching Phase 3 trials. The company also advanced products for arthritis, neuropathic pain, headache, and other pain-related indications. Many programs are no longer active, and no recent clinical results or active trials are reported. Status is likely discontinued.
- Therapeutic areas
- DermatologyImmunologyGastroenterologyNeurologyOncologyRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Winston Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Winston Pharmaceuticals.